JP2017514855A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514855A5
JP2017514855A5 JP2016566649A JP2016566649A JP2017514855A5 JP 2017514855 A5 JP2017514855 A5 JP 2017514855A5 JP 2016566649 A JP2016566649 A JP 2016566649A JP 2016566649 A JP2016566649 A JP 2016566649A JP 2017514855 A5 JP2017514855 A5 JP 2017514855A5
Authority
JP
Japan
Prior art keywords
cycloalkyl
alkyl
alkylene
haloalkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566649A
Other languages
English (en)
Japanese (ja)
Other versions
JP6728061B2 (ja
JP2017514855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/029240 external-priority patent/WO2015171610A2/en
Publication of JP2017514855A publication Critical patent/JP2017514855A/ja
Publication of JP2017514855A5 publication Critical patent/JP2017514855A5/ja
Application granted granted Critical
Publication of JP6728061B2 publication Critical patent/JP6728061B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566649A 2014-05-05 2015-05-05 ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療 Expired - Fee Related JP6728061B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461988710P 2014-05-05 2014-05-05
US61/988,710 2014-05-05
US201562121800P 2015-02-27 2015-02-27
US62/121,800 2015-02-27
PCT/US2015/029240 WO2015171610A2 (en) 2014-05-05 2015-05-05 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease

Publications (3)

Publication Number Publication Date
JP2017514855A JP2017514855A (ja) 2017-06-08
JP2017514855A5 true JP2017514855A5 (enExample) 2018-06-14
JP6728061B2 JP6728061B2 (ja) 2020-07-22

Family

ID=54393134

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566649A Expired - Fee Related JP6728061B2 (ja) 2014-05-05 2015-05-05 ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療

Country Status (6)

Country Link
US (3) US9896441B2 (enExample)
EP (1) EP3140291A4 (enExample)
JP (1) JP6728061B2 (enExample)
AU (1) AU2015256190B2 (enExample)
CA (1) CA2947290A1 (enExample)
WO (1) WO2015171610A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
AU2016257997A1 (en) * 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
WO2019040842A1 (en) * 2017-08-25 2019-02-28 Lycera Corporation TREATMENT OF CANCER USING ARYL SULFONAMIDE DIHYDRO-2H-BENZO [B] [1,4] OXAZINE COMPOUNDS
US11396503B2 (en) 2017-09-30 2022-07-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Sulfonyl substituted bicyclic compound which acts as ROR inhibitor
WO2019121143A1 (en) 2017-12-20 2019-06-27 Basf Se Substituted cyclopropyl derivatives
WO2019164788A1 (en) * 2018-02-20 2019-08-29 Lycera Corporation Methods of treating cancer using aryl dihydro-2h-benzo[b] [1,4]oxazine sulfonamide compounds
CN109568321B (zh) * 2019-01-14 2022-02-22 山东轩竹医药科技有限公司 RORγ调节剂
KR102554782B1 (ko) * 2019-01-23 2023-07-13 아비스코 테라퓨틱스 컴퍼니 리미티드 1,2,3,4-테트라히드로퀴녹살린 유도체, 이의 제조 방법 및 응용
WO2021047406A1 (zh) * 2019-09-10 2021-03-18 四川科伦博泰生物医药股份有限公司 一种三并环类化合物，包含其的药物组合物，其制备方法及其用途
CN111671909B (zh) * 2020-06-22 2022-06-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 他汀类药物联合ror激动剂在治疗结直肠癌方面的应用
CN113173939B (zh) * 2021-04-01 2022-07-05 常州大学 一种铜催化三组分反应合成三取代烯基硼酸酯的方法
CN115557913A (zh) * 2021-07-02 2023-01-03 广东东阳光药业有限公司 苯并氮杂环类化合物及其在药物中的应用
WO2023016530A1 (zh) * 2021-08-13 2023-02-16 南京明德新药研发有限公司 一类3,4-二氢-2H-苯并[b][1,4]噁嗪类化合物及其制备方法
WO2023016528A1 (zh) * 2021-08-13 2023-02-16 南京明德新药研发有限公司 一类苯并吗啉类化合物及其制备方法和用途
WO2023016527A1 (zh) * 2021-08-13 2023-02-16 南京明德新药研发有限公司 一类苯并噁嗪螺环类化合物及其制备方法
CN118005596A (zh) * 2023-05-24 2024-05-10 内蒙古大学 一种钯催化制备β-榄香烯色满醇类衍生物的方法
WO2025262003A1 (en) * 2024-06-19 2025-12-26 F. Hoffmann-La Roche Ag Dihydro benzoxazine derivatives
WO2026087635A1 (en) * 2024-10-24 2026-04-30 F. Hoffmann-La Roche Ag Dihydro benzoxazine derivatives

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2236930A1 (de) 1971-08-03 1973-02-15 Cameroun Etat Verfahren zur herstellung von desmosterol
GB1447456A (en) 1973-06-20 1976-08-25 Teijin Ltd Process for preparing desmosterols
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DE3823318A1 (de) 1988-07-09 1990-02-22 Bayer Ag (hetero)aryloxynaphthaline mit ueber schwefel gebundenen substituenten
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
WO1992012726A1 (en) 1991-01-16 1992-08-06 Schering Corporation Use of interleukin-10 in adoptive immunotherapy of cancer
TW263508B (enExample) 1991-02-12 1995-11-21 Pfizer
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
JP3414433B2 (ja) 1993-03-01 2003-06-09 日本化薬株式会社 電子写真用トナー
DE19523446A1 (de) 1995-06-28 1997-01-02 Bayer Ag Benzotriazole
US6037367A (en) 1995-07-14 2000-03-14 Smithkline Beecham Corporation Substituted-pent-4-ynoic acids
IL122944A (en) 1995-08-10 2001-11-25 Bayer Ag Halogenobenzimidazoles, their preparation and microbicidal compositions containing them
EP0882718B1 (en) 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
WO1997048672A2 (en) * 1996-06-21 1997-12-24 Allergan Sales, Inc. Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
DE69728688T2 (de) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
US6392010B1 (en) 1996-12-19 2002-05-21 Aventis Pharmaceuticals Inc. Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
HK1039325B (en) 1998-09-18 2006-02-24 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidines as kinase inhibitors
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EE200200070A (et) 1999-08-13 2003-04-15 Biogen, Inc. Raku adhesiooni inhibiitorid
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
WO2002014361A2 (en) 2000-08-17 2002-02-21 Agensys, Inc. NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
DE60136490D1 (de) 2000-11-09 2008-12-18 Neopharm Inc Sn-38-lipidkomplexe und verfahren zu ihrer verwendung
TWI239942B (en) 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
CN1304390C (zh) 2001-08-03 2007-03-14 先灵公司 新颖的γ—分泌酶抑制剂
KR100879693B1 (ko) 2001-08-17 2009-01-21 상꾜 아그로 가부시키가이샤 2-시클로프로필-6-메틸페놀
WO2003104428A2 (en) 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
DE10229777A1 (de) 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
AU2003303231A1 (en) * 2002-12-20 2004-07-14 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
JP4601038B2 (ja) 2003-03-26 2010-12-22 第一三共株式会社 インドリルマレイミド類
US20080199486A1 (en) 2003-05-12 2008-08-21 Yair Argon Grp94-based compositions and methods of use thereof
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
CN1874780A (zh) 2003-09-26 2006-12-06 福布斯梅迪泰克公司 抑制多抗药性基因表达并抑制由该基因表达导致的蛋白质产生从而提高化学治疗剂治疗癌症有效性的方法
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
SE0302760D0 (sv) 2003-10-20 2003-10-20 Biovitrum Ab New compounds
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP4527730B2 (ja) 2003-12-09 2010-08-18 エフ．ホフマン−ラ ロシュ アーゲー ベンゾオキサジン誘導体及びその使用
AU2004309420B2 (en) 2003-12-23 2008-10-30 Novartis Ag Bicyclic heterocyclic p-38 kinase inhibitors
WO2005084208A2 (en) 2004-02-27 2005-09-15 New York University A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
WO2005120558A2 (en) 2004-05-25 2005-12-22 University Of Connecticut Health Center Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
JP2008505080A (ja) 2004-07-01 2008-02-21 ニューヨーク ユニバーシティー ＲＯＲγｔ機能の調節のための組成物および方法
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
US20070010537A1 (en) 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
US7304073B2 (en) 2004-08-20 2007-12-04 Wyeth Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors
US7652043B2 (en) 2004-09-29 2010-01-26 The Johns Hopkins University WNT pathway antagonists
CA2590401C (en) 2004-10-08 2015-04-21 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Adoptive immunotherapy with enhanced t lymphocyte survival
ES2601896T3 (es) 2004-11-24 2017-02-16 Fred Hutchinson Cancer Research Center Procedimientos de uso de la IL-21 en la inmunoterapia adoptiva y la identificación de antígenos tumorales
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
GB0514911D0 (en) 2005-07-20 2005-08-24 Univ Birmingham T cell memory assay
WO2007024944A1 (en) 2005-08-25 2007-03-01 Schering Corporation Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
SI1937669T1 (sl) 2005-09-01 2012-05-31 Janssen Pharmaceutica Nv Novi derivati benzopirana kot odpiralci kalijevega kanala
CN101263116B (zh) 2005-09-15 2011-12-07 霍夫曼-拉罗奇有限公司 可用作肝肉碱棕榈酰转移酶抑制剂的新型杂双环衍生物
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
WO2007093507A1 (en) 2006-02-13 2007-08-23 F. Hoffmann-La Roche Ag Heterobicyclic sulfonamide derivatives for the treatment of diabetes
JP4653842B2 (ja) 2006-02-17 2011-03-16 ライジェル ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患を治療または予防するための２，４−ピリミジンジアミン化合物
US7993638B2 (en) 2006-03-01 2011-08-09 Janssen Pharmaceutica Nv Cancer treatment combining lymphodepleting agent with CTLs and cytokines
EP2005177B1 (en) 2006-04-06 2013-07-10 Janssen R&D Ireland A homogeneous time resolved fluorescence based test method
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
US20080305169A1 (en) 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
BRPI0712730A2 (pt) 2006-06-01 2013-12-17 Wyeth Corp Composto da fórmula i; método para o tratamento de um distúrbio do sistema nervoso central relacionado ou afetado pelo receptor 5-ht6 em um paciente que dele necessita; composição farmacêutica; processo para a preparação de um composto da fórmula ia; e uso de um composto da fórmula i
AU2007271188B2 (en) 2006-07-03 2012-11-01 Proximagen Limited Indoles as 5-HT6 modulators
CA2655042A1 (en) 2006-07-12 2008-01-17 Oncotx, Inc. Compositions and methods for targeting cancer-specific transcription complexes
TWI315304B (en) 2006-08-31 2009-10-01 Univ Taipei Medical Indoline-sulfonamides compounds
US8389739B1 (en) 2006-10-05 2013-03-05 Orphagen Pharmaceuticals Modulators of retinoid-related orphan receptor gamma
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
WO2008062740A1 (fr) 2006-11-20 2008-05-29 Japan Tobacco Inc. Composé azoté à anneaux fusionnés et son utilisation
US7799933B2 (en) 2006-12-21 2010-09-21 Hoffman-La Roche Inc. Sulfonamide derivatives
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EP2154965A4 (en) 2007-05-29 2011-08-17 Glaxosmithkline Llc NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS
JP2010529843A (ja) 2007-06-03 2010-09-02 オンコティーエックス インコーポレイテッド バイオマーカーおよび薬物標的としての、転写因子複合体の構成要素のがん関連アイソフォーム
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
US20110190280A1 (en) 2007-08-29 2011-08-04 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
WO2009035997A2 (en) 2007-09-14 2009-03-19 Cara Therapeutics, Inc. Benzo-fused heterocycles
EP2203746B1 (en) 2007-09-24 2013-03-06 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
US20090131523A1 (en) 2007-10-15 2009-05-21 Enzymotec Ltd. Lipid compositions for the treatment and prevention of proliferative diseases and for the reduction of incidences of mutagenesis and carinogenesis
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
US7960377B2 (en) 2008-03-28 2011-06-14 Cara Therapeutics, Inc. Substituted pyridoxazines
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
EP2300437B1 (en) 2008-06-05 2013-11-20 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
WO2009149819A1 (en) 2008-06-09 2009-12-17 Sanofi-Aventis Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
BRPI0914978A2 (pt) 2008-06-09 2015-10-27 Sanofi Aventis sulfonamidas n-heterocíclicas reforçadas com grupo principal de oxadiazolona, processos para sua preparação e seu uso como farmacêuticos
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
CA2973871C (en) 2008-07-09 2019-09-10 Nissan Chemical Industries, Ltd. Production method of isoxazoline-substituted benzoic acid amide compound
WO2010017827A1 (en) 2008-08-14 2010-02-18 European Molecular Biology Laboratory 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
CA2736851A1 (en) 2008-09-11 2010-03-18 Lung-Ji Chang System and method for producing t cells
SI2344471T1 (sl) 2008-10-02 2013-11-29 Taisho Pharmaceutical Co., Ltd. Derivat 7-piperidinoalkil-3,4-dihidrokvinolona
EP2181710A1 (en) 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
WO2010057101A2 (en) 2008-11-17 2010-05-20 Schering Corporation Compounds useful as hiv blockers
CA2743609A1 (en) 2008-11-19 2010-05-27 Schering Corporation Inhibitors of diacylglycerol acyltransferase
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
EA021424B1 (ru) 2008-12-19 2015-06-30 Сертрис Фармасьютикалз, Инк. Тиазолопиридиновые соединения, регулирующие сиртуин
TW201030007A (en) 2009-02-06 2010-08-16 Gruenenthal Gmbh Substituted spiro-amides as b1r modulators
EP2406255B1 (en) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
WO2010117425A1 (en) 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
WO2010123139A1 (ja) 2009-04-24 2010-10-28 持田製薬株式会社 スルファモイル基を有するアリールカルボキサミド誘導体
AR076435A1 (es) 2009-04-30 2011-06-08 Glaxo Group Ltd Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
DK2462165T3 (en) 2009-08-03 2016-08-29 Univ Miami Method for in vivo proliferation of regulatory T cells
WO2011019634A2 (en) 2009-08-10 2011-02-17 Taipei Medical University Aryl substituted sulfonamide compounds and their use as anticancer agents
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
EP2947073B1 (en) 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
JP2013512878A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド 新規化合物
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20110142814A1 (en) 2009-12-16 2011-06-16 New York University Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy
KR101939704B1 (ko) 2010-03-01 2019-01-17 지티엑스, 인코포레이티드 암 치료용 화합물
PT2542590T (pt) 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201013443D0 (en) 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
JP5876051B2 (ja) 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
RS54286B1 (sr) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2012129394A2 (en) 2011-03-22 2012-09-27 Brigham And Women's Hospital, Inc. Methods and compositions for the treatment of cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
EP3616701A1 (en) 2011-06-24 2020-03-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
AU2012311599B2 (en) 2011-09-19 2017-07-06 Eth Zurich Ror gamma modulators
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
KR20140135251A (ko) 2012-03-16 2014-11-25 코바겐 아게 항종양 활성이 있는 신규 결합 분자
AU2013259904A1 (en) 2012-05-08 2014-10-02 Lycera Corporation Bicyclic sulfone compounds for inhibition of RORy activity and the treatment of disease
WO2013167136A1 (en) 2012-05-08 2013-11-14 Herlev Hospital Improving adoptive cell therapy with interferon gamma
MX367341B (es) 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
WO2013169864A2 (en) * 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
WO2013176740A1 (en) 2012-05-25 2013-11-28 Health Diagnostic Laboratory, Inc. Rapid and high-throughput analysis of sterols/stanols or derivatives thereof
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014028669A1 (en) 2012-08-15 2014-02-20 Biogen Idec Ma Inc. Novel compounds for modulation of ror-gamma activity
WO2014026328A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EP2931267A1 (en) 2012-12-17 2015-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
AU2015222917A1 (en) * 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease

Similar Documents

Publication Publication Date Title
JP2023518286A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2016519072A5 (enExample)
RU2014114466A (ru) ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА
JP2016525075A5 (enExample)
IL296199A (en) Salt form of human histone methyltransferase inhibitor 2ezh
RU2016134749A (ru) Гетероциклическое сульфонамидное производное и лекарственное средство, содержащее такое производное
JP2016515560A5 (enExample)
JP2018516963A5 (enExample)
JP2014525420A5 (enExample)
EA036672B8 (ru) Ингибиторы лизин-специфической деметилазы-1
JP2015531366A5 (enExample)
MX2013005008A (es) Derivados de carboxamida y urea heteroaromaticos sustituidos como ligandos del receptor vanilloide.
JP2013525458A5 (enExample)
EA201290260A1 (ru) Бензимидазол-имидазольные производные
PH12015501567B1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
JP2016505586A5 (enExample)
JP2016534134A5 (enExample)
JP2017509586A5 (enExample)
JP2016506960A5 (enExample)
JP2016503799A5 (enExample)
JP2016512520A5 (enExample)
ME02382B (me) 2-(2,4,5-supstituisani-anilino) piramidisnki derivati kao egfr modulatori korisni za tretman raka
EA201492255A1 (ru) Феноксиэтилпиперидиновые соединения
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы